title: Risk factors for failure in early prosthetic joint infection treated with debridement. Influence of etiology and antibiotic treatment.
abstract: OBJECTIVE
  The aim of the present study was to evaluate the importance of isolated microorganisms according to the Gram stain and the type of antibiotic received on the outcome of early prosthetic joint infection (PJI) treated with debridement, antibiotics and implant retention (DAIR).
  
  
  METHODS
  From January 1999 to December 2009, all patients with an early PJI were prospectively registered in a database and they were retrospectively reviewed for this study.
  
  
  RESULTS
  During the study period, 160 patients met the inclusion criteria of the study. After a mean (SD) post-debridement follow-up of 5.2 (2.5) years, 117 patients (73.1%) were considered to be in remission and 43 (26.9%) were classified as failure. Variables associated with failure were liver cirrhosis (66.7% vs. 22.8%, p=0.001), diagnosis within the first 30 days from arthroplasty (30.4% vs. 8.0%, p=0.020), C-reactive protein (CRP) >12 mg/dl (46.7% vs. 21.2%, p=0.005), microorganism isolated in all deep samples (31.1% vs. 16.0%, p=0.047) and Gram-negative (GN) infection not treated with a fluoroquinolone (57.1% vs. 20.0%, P=0.004). Gram-positive (GP) infection not treated with rifampin was close to be statistically significantly associated with failure (34.4% vs. 19.2%, p=0.067). A multivariate analysis identified liver cirrhosis (OR: 12.4 CI95%: 3.1-49.7, p<0.001), CRP-value (OR: 1.06 CI95%: 1.0-1.11, p=0.049), and when a GN-infection was not treated with a fluoroquinolone (OR: 6.5, CI95%: 1.8-23.8, p=0.005) as independent predictors of failure.
  
  
  CONCLUSIONS
  The remission rate of PJI treated with DAIR after 3 years of follow-up was 73%. The main predictors of failure were liver cirrhosis, the selected antibiotic most specially fluoroquinolones for GN and rifampin for GP infections, the C-reactive protein and the number of samples culture positive as a potential surrogate markers of bacterial density.
authors.affiliation: 1 Department of Orthopedic and Trauma Surgery, Hospital Clínic of Barcelona, Barcelona - Spain.
authors.forename: Eduard
authors.initials: E
authors.lastname: Tornero
authors.forename: Juan C
authors.initials: JC
authors.lastname: Martínez-Pastor
authors.forename: Guillem
authors.initials: G
authors.lastname: Bori
authors.forename: Sebastián
authors.initials: S
authors.lastname: García-Ramiro
authors.forename: Laura
authors.initials: L
authors.lastname: Morata
authors.forename: Jordi
authors.initials: J
authors.lastname: Bosch
authors.forename: Josep
authors.initials: J
authors.lastname: Mensa
authors.forename: Alex
authors.initials: A
authors.lastname: Soriano
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy*; D015984:Causality; D015897:Comorbidity; D003646:Debridement / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D015994:Incidence; D008103:Liver Cirrhosis / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D008137:Longitudinal Studies; D008297:Male; D016459:Prosthesis-Related Infections / Q000453:epidemiology / Q000382:microbiology / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents